New Delhi: The Covaxin Phase-III trial, which was made by Bharat Biotech Hyderabad showed that 93.4% was effective against severe simptomatic Covid-19, the company said on Saturday.
Data shows the protection of 65.2% of Delta variants, first identified in India.
The Delta variant has led to a surge in infection in April and May, and the highest daily toll in the world.
Furthermore, it showed the effectiveness of 77.8% against Simtomatic Covid-19 in the trial.
Last month, Astrazeneca vaccine maker also said the vaccine was effective against the Delta and Kappa variants, citing a study.
This country has provided astrazeneca vaccines, made domestically by the Indian Serum Institute, which plans to increase monthly production from July, to almost 100 million doses.
Bharat Biotech now estimates that it will produce 23 million doses a month.
Data Phase-III comes as Ocugen Inc., which is co-developing Covaxin with Bharat Biotech for the US market, preparing to submit a request for US full approval.
India, with the calculation of 30.45 million infections, is the country most affected by the United States, with 33 million.
The death toll of South Asian countries has now passed 400,000.
Bharat Biotech said the vaccine was 93.4% effective against severe Covid-19
